Financial Performance - The company's operating revenue for Q1 2021 was ¥1,216,722,019.77, representing a 33.70% increase compared to ¥910,027,853.40 in the same period last year[9]. - Net profit attributable to shareholders was ¥225,869,003.12, up 46.53% from ¥154,143,953.63 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥215,120,160.37, reflecting a 47.32% increase from ¥146,023,980.47 in the previous year[9]. - The basic earnings per share increased to ¥0.39, a rise of 44.44% compared to ¥0.27 in the same period last year[9]. - Total operating revenue for the current period reached CNY 1,216,722,019.77, a significant increase from CNY 910,027,853.40 in the previous period, representing a growth of approximately 33.6%[75]. - Total operating costs amounted to CNY 906,568,193.56, up from CNY 710,432,872.34, indicating an increase of about 27.6%[78]. - Net profit for the current period was CNY 243,082,530.17, compared to CNY 161,002,031.79 in the previous period, reflecting a growth of approximately 50.9%[81]. - Total comprehensive income attributable to the parent company was CNY 225,888,266.00, up from CNY 154,353,763.23 in the previous period, representing an increase of approximately 46.3%[85]. - Basic and diluted earnings per share both increased to CNY 0.39 from CNY 0.27, reflecting a growth of 44.4%[85]. Cash Flow - The net cash flow from operating activities was ¥220,961,896.05, down 10.89% from ¥247,958,852.87 year-on-year[9]. - The net cash flow from investment activities was -¥8,108.26 million, a decrease of 145.70% compared to -¥3,300.02 million in the previous period, mainly due to cash outflow for purchasing financial products[24]. - The company’s cash flow from financing activities showed a drastic decline of -1040.96%, from ¥1,844.39 million to -¥17,354.93 million, primarily due to a decrease in cash inflow from financing activities[24]. - The net cash flow from financing activities was -173,549,308.13, compared to 18,443,850.63 in the previous period, indicating a significant decrease in financing cash flow[99]. - The cash flow from investment activities showed a net outflow of -52,360,337.90, contrasting with a net inflow of 107,333,449.10 in the previous period, indicating a shift in investment cash flow dynamics[103]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,114,662,089.14, a slight increase of 0.03% from ¥5,113,343,143.57 at the end of the previous year[9]. - The company's current assets totaled CNY 2,923,777,259.19, compared to CNY 2,937,267,451.04 at the end of 2020, indicating a decrease of approximately 0.46%[57]. - Total liabilities decreased to CNY 1,481,736,167.69 from CNY 1,722,583,177.34, marking a reduction of about 14.00%[63]. - The company's total assets decreased to CNY 3,247,711,243.45 from CNY 3,439,290,879.02, a decline of about 5.6%[73]. - Total liabilities decreased to CNY 1,024,153,277.37 from CNY 1,216,175,578.37, representing a reduction of approximately 15.8%[73]. - The company's equity attributable to shareholders rose to CNY 3,405,265,016.64 from CNY 3,180,232,064.90, an increase of approximately 7.06%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,748[14]. - The company repurchased a total of 3,838,503 shares during the reporting period, accounting for 0.66% of the total share capital, with a total expenditure of ¥56.33 million[28]. - The company has committed to repurchase all newly issued shares if there are false records or misleading statements in the prospectus, with the repurchase price not lower than the issuance price plus interest from the listing date to the repurchase offer date[34]. - The commitment to repurchase shares must be executed within 30 trading days after the shareholders' meeting approval, with a repurchase price based on the higher of the issuance price plus interest or the average weighted price over the last 30 trading days prior to the regulatory investigation[34]. - The company has a long-term commitment to compensate investors for losses incurred due to false records or misleading statements in the prospectus[34]. Government and Regulatory Compliance - The company received government subsidies amounting to ¥50,453,813.28 during the reporting period[9]. - The company has ongoing commitments to ensure compliance with legal regulations regarding share repurchase and investor compensation[34]. - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares, accepting supervision from regulatory authorities and investors[34]. - The company has not experienced any non-operational fund occupation by controlling shareholders during the reporting period[49]. Operational Insights - The company has engaged in multiple investor communications regarding financial data and operational performance throughout January 2021[50]. - The company has plans for future market expansion and product development, although specific details were not disclosed in the report[66]. - The company has implemented new leasing standards effective from January 1, 2021, which may impact future financial reporting[114].

Financial Performance - The company's operating revenue for 2020 was ¥3,461,888,347.20, a decrease of 20.81% compared to ¥4,371,413,641.89 in 2019[27]. - The net profit attributable to shareholders of the listed company was ¥584,454,186.65, an increase of 3.37% from ¥565,422,018.73 in 2019[27]. - The net profit after deducting non-recurring gains and losses was ¥474,091,995.04, down 5.31% from ¥500,681,508.67 in 2019[27]. - The net cash flow from operating activities increased by 19.21% to ¥1,169,867,011.53 from ¥981,327,677.71 in 2019[27]. - The basic earnings per share for 2020 was ¥1.00, up 3.09% from ¥0.97 in 2019[27]. - Total assets at the end of 2020 were ¥5,113,343,143.57, a decrease of 3.69% from ¥5,309,290,285.34 at the end of 2019[27]. - The net assets attributable to shareholders of the listed company were ¥3,180,232,064.90, down 1.36% from ¥3,224,119,367.21 at the end of 2019[27]. - The company achieved total revenue of CNY 346,188.83 million in 2020, a decrease of 20.81% compared to the previous year[54]. - Operating profit was CNY 76,662.19 million, an increase of 0.82% year-on-year[54]. - Net profit attributable to shareholders was CNY 58,445.42 million, reflecting a growth of 3.37% compared to the previous year[54]. Dividend Distribution - The company reported a cash dividend of 3.5 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[7]. - The company distributed a cash dividend of 10 yuan (including tax) for every 10 shares for the 2019 fiscal year, totaling 58.4 million yuan[147]. - For the 2020 fiscal year, the company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares, with a total cash dividend amount of 201.9 million yuan[149]. - The total cash dividend for 2020, including other methods, amounts to 285.5 million yuan, representing 48.84% of the distributable profit[154]. - The cash dividend for 2019 was 582.4 million yuan, which exceeded the net profit attributable to ordinary shareholders by 103.01%[153]. - The company has established a three-year dividend return plan (2020-2022) to ensure the continuity and stability of its dividend distribution policy[147]. - The cash dividend policy is compliant with the company's articles of association and has been approved by the shareholders' meeting[148]. - The company aims to protect the interests of shareholders, especially small and medium-sized investors, through its dividend distribution plan[147]. Market Strategy and Expansion - The company aims to enhance its market expansion and product development strategies in the upcoming fiscal year[7]. - The company is focusing on expanding its gynecological and chronic disease medication categories to complement its pediatric offerings[41]. - The company is actively engaged in drug research and development, highlighting its commitment to innovation in the pharmaceutical sector[133]. - The company is focused on the overseas sales of its products, indicating a strategic push for international market expansion[133]. - Market expansion plans include entering two new international markets by Q3 2021, projected to increase market share by 5%[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $30 million allocated for potential deals[132]. - The company is exploring potential market expansion opportunities to drive growth[140]. Risk Management - The company faced risks including industry policy changes, raw material price fluctuations, and uncertainties due to the pandemic[7]. - The company emphasizes the importance of risk awareness among investors regarding future development plans[7]. - Strategic reserves for core raw materials will be established to mitigate procurement risks associated with price volatility[124]. - The company will closely monitor industry policy dynamics and adjust its operational strategies accordingly to enhance core competitiveness[124]. - The company is actively monitoring the impact of the COVID-19 pandemic on product sales and overall performance[136]. Research and Development - The company has initiated the development of over 20 new chemical drugs, with more than 10 products currently in the research phase[60]. - The company is focusing on developing new products, including Ibuprofen suspension and liver protection tablets, with ongoing clinical trials[79]. - The company has implemented a five-pronged channel management strategy, enhancing coverage in hospitals and retail markets across all provinces except Tibet[55]. - The company has improved its production quality control, achieving a reduction in manufacturing costs while maintaining safety standards[56]. - The company is committed to enhancing the safety and efficacy of its children's medications, ensuring they meet high-quality standards[47]. Corporate Governance - The company’s legal representative is Guan Yuxiu, who oversees the strategic direction and governance[20]. - The company is preparing for its shareholder meeting, which will address dividend distribution and other key matters[133]. - The company is monitoring the shareholding structure and stock price trends closely, reflecting its attention to market dynamics[133]. - The company confirmed that it has fulfilled its commitments to minority shareholders in a timely manner[166]. - The actual controller of the company, Guan Yanbin, was sentenced to 11 years in prison for intentional homicide, but this incident did not affect the company's normal operations[177][180]. Financial Management - The company has established a dedicated management system for the raised funds to ensure their effective use and safeguard investor interests[101]. - The company has not reported any overdue commitments that remain unfulfilled[164]. - The company has diversified its investments across various asset classes, including money market assets and bonds[200]. - The management strategy focuses on maximizing returns while maintaining liquidity and safety in cash asset management[197]. - The company has utilized idle self-owned funds for all entrusted financial products, ensuring liquidity[197]. Operational Performance - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q4 2020[132]. - User data showed a 15% increase in active users, reaching a total of 5 million by the end of the fiscal year[132]. - The company provided guidance for the next quarter, expecting revenue growth of 20% compared to the previous quarter[132]. - The impact of the pandemic on production was minimal, with production capacity maintained at 90% throughout the year[132]. - Customer satisfaction ratings improved by 12%, reflecting the effectiveness of recent service enhancements[132].

股票代码：002737 股票简称：葵花药业 公告编号：2020-084 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，葵花药业集团股份有限公司（以下简称 "公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举办 的"黑龙江省上市公司 2020 年度投资者网上集体接待日"活动，现将有关事项 公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司 本次投资者集体接待日活动，时间为 2020 年 11 月 12 日 14:00 至 16:30。 届时公司副总经理（副总裁）、财务负责人李金明先生，董事会秘书田艳女 士将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融资 情况和可持续发展等投资者关注的问题进行交流。期间，公司高管将全程在线， 实时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 葵花药业集团股份有限公司 董事会 2020 年 11 月 ...

Financial Performance - Operating revenue for the reporting period was approximately ¥606.23 million, a decrease of 20.66% compared to the same period last year[10]. - Net profit attributable to shareholders of the listed company was approximately ¥79.71 million, an increase of 17.53% year-on-year[10]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥70.89 million, an increase of 38.39% compared to the same period last year[10]. - Basic earnings per share were ¥0.1369, an increase of 17.51% compared to the same period last year[10]. - The company reported a total comprehensive income of ¥87,074,676.08 for the current period, compared to ¥88,814,228.90 in the previous period[94]. - The net profit from continuing operations for the third quarter was approximately CNY 598.83 million, compared to CNY 369.78 million in the same period last year, representing a year-on-year increase of 62%[116]. - The company reported a decrease in unallocated profits from CNY 1,485,566,243.89 to CNY 1,219,928,400.65, a reduction of about 17.9%[77]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.87 billion, a decrease of 8.18% compared to the end of the previous year[10]. - Net assets attributable to shareholders of the listed company were approximately ¥2.94 billion, down 8.81% year-on-year[10]. - The company's total liabilities decreased by 68.86% in employee compensation to ¥7,808,227, due to the payment of last year's bonuses[23]. - Total liabilities decreased from CNY 1,879,642,335.60 to CNY 1,733,264,017.32, a decrease of approximately 7.8%[74]. - Owner's equity decreased from CNY 3,429,647,949.74 to CNY 3,141,706,863.37, reflecting a decline of about 8.4%[76]. - The total current assets decreased from CNY 1,820,904,704.79 to CNY 1,698,832,298.02, a decline of approximately 6.7%[78]. Cash Flow - Net cash flow from operating activities was approximately ¥195.76 million, an increase of 705.55% year-on-year[10]. - The net cash flow from operating activities increased by 45.27% to ¥649,423,777, primarily due to a decrease in cash payments for goods and services[25]. - Cash inflow from operating activities totaled CNY 2.78 billion, down 16.3% from CNY 3.32 billion in the previous year[119]. - The company reported a net cash outflow from investing activities of approximately CNY 467.79 million, worsening from a net outflow of CNY 321.70 million in the previous year[122]. - The total cash and cash equivalents at the end of the period were 801,604,509.29 CNY, down from 1,152,371,472.96 CNY at the beginning of the period, reflecting a decrease of approximately 30.4%[127]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,942[15]. - The largest shareholder, Sunflower Group Co., Ltd., held 45.41% of the shares, amounting to 265,200,000 shares[15]. - The company repurchased a total of 3,291,557 shares, accounting for 0.56% of the current total share capital, with a total expenditure of 50 million CNY (excluding transaction fees)[30]. - The company has committed to repurchase shares if any false statements or omissions are found in the prospectus, with a repurchase price not lower than the public offering price plus interest[34]. Investment and Projects - The company has outlined a plan for the use of raised funds, with specific projects under consideration for investment[44]. - The acquisition of Jilin Jianjin Pharmaceutical Co., Ltd. involved a total investment of RMB 10,905.90 million, with 100% of the funds utilized[50]. - The company plans to permanently supplement working capital with surplus funds from completed projects, totaling RMB 9,753.90 million[49]. - The company has engaged in entrusted wealth management with a total amount of 60,000,000 CNY, with 50,000,000 CNY remaining unexpired[53]. Operational Challenges - The company reported a 40.83% decrease in selling expenses to ¥554,526,092, attributed to reduced sales activities due to the COVID-19 pandemic[23]. - The company is assessing the ongoing impact of the pandemic and its response strategies[64]. - The company anticipates potential losses or significant changes in net profit compared to the same period last year[53].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2020, representing a year-on-year increase of 15%[20]. - Net profit attributable to shareholders reached RMB 200 million, up 10% compared to the same period last year[20]. - The company's operating revenue for the reporting period was ¥1,600,107,144.68, a decrease of 32.97% compared to the same period last year[27]. - Net profit attributable to shareholders was ¥237,075,552.49, down 22.40% year-over-year[27]. - The total profit amounted to CNY 31,975,470, a decline of 24.28% year-on-year[48]. - Net profit attributable to shareholders was CNY 23,707,560, reflecting a decrease of 22.40% compared to the previous year[48]. - The net profit after deducting non-recurring gains and losses was ¥220,058,096.61, reflecting an 18.76% decline compared to the previous year[27]. - The gross profit margin improved to 45%, up from 42% in the previous year, indicating better cost management[20]. Market Expansion and Product Development - The company plans to expand its market presence by increasing the number of retail pharmacies by 20% by the end of 2020[20]. - The company has launched two new products in the pediatric medicine segment, contributing to a 25% increase in sales in that category[20]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[20]. - The company has increased investment in new product development and marketing strategies to strengthen its competitive advantage in the pharmaceutical industry[38]. - The company expanded its probiotic product line and optimized its product structure to enhance market coverage[48]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation[20]. - Research and development investment was CNY 45,172,529, down 29.97% year-on-year[52]. Cash Flow and Assets - The net cash flow from operating activities increased by 7.32% to ¥453,665,935.46[27]. - Total assets at the end of the reporting period were ¥4,774,300,049.21, a decrease of 10.08% from the end of the previous year[27]. - The net assets attributable to shareholders decreased by 10.65% to ¥2,880,652,010.14[27]. - Cash and cash equivalents at the end of the reporting period were ¥1,052,047,222.13, down 2.52% from ¥1,240,398,231.93 in the previous year[60]. - Inventory decreased to ¥637,831,129.14, representing 13.36% of total assets, down from 15.08%[60]. Environmental Compliance and Social Responsibility - The company has maintained compliance with environmental regulations, achieving standard emissions for wastewater, waste gas, noise, and solid waste, with no pollution incidents reported[152]. - The company actively engaged in social responsibility initiatives, including cash donations and employment support for poverty alleviation, particularly through its subsidiary in Guizhou[153]. - The company has donated over 20 batches of anti-epidemic materials in response to the COVID-19 pandemic, demonstrating its commitment to public health[153]. - The company provided financial assistance of 74,400 RMB to impoverished areas and employed 4 individuals from poverty-stricken households[157]. - The company plans to continue participating in national poverty alleviation efforts and actively undertake social responsibilities[158]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[97]. - The company has ongoing commitments related to the issuance of shares and will repurchase shares if there are false statements in the prospectus[98]. - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares[104]. - The company reported a procurement transaction with a related party, purchasing rice at a price of 9.6 CNY per kilogram, totaling 6,334,000 CNY, which accounts for 1.07% of similar transaction amounts[117]. - The total number of shareholders at the end of the reporting period was 48,127[176]. - The largest shareholder, Guo Yanbin, holds 51.85% of the shares, while the second-largest shareholder, Heilongjiang Jinkui Investment Co., Ltd., holds 21.78%[179]. - The company has a total of 265,200,000 shares pledged, which is 45.41% of the shares held by the largest shareholder[180]. - The company plans to continue its share repurchase program in accordance with relevant laws and regulations[174]. Risks and Challenges - The company is facing risks related to industry policy changes, fluctuations in traditional Chinese medicine prices, and uncertainties due to the pandemic[91]. - The company plans to strategically reserve core medicinal materials and optimize its product sales structure to mitigate risks[91].

Financial Performance - The company's operating revenue for Q1 2020 was ¥910,027,853.40, a decrease of 24.96% compared to ¥1,212,749,716.64 in the same period last year[10] - Net profit attributable to shareholders was ¥154,143,953.63, down 5.46% from ¥163,053,433.01 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥146,023,980.47, a decrease of 5.98% compared to ¥155,304,348.18 in the previous year[10] - Basic earnings per share were ¥0.26, down 7.14% from ¥0.28 in the same period last year[10] - The weighted average return on net assets was 4.67%, a decrease of 0.19% compared to 4.86% in the previous year[10] - The total sales expenses for the first quarter were CNY 221,472,557.56, a decrease of 38.14% compared to the previous year due to the impact of the COVID-19 pandemic[23] - The company reported a significant increase in other operating expenses, which rose by 1404.90% to CNY 1,062,291.97, largely due to donations made in response to the COVID-19 pandemic[23] - The total profit for the first quarter was 204,058,184.40, down from 219,299,564.72, which is a decrease of approximately 6.5%[80] - The total comprehensive income for the first quarter was 161,211,841.39, down from 177,938,631.59, reflecting a decrease of about 9.48%[83] Cash Flow - The net cash flow from operating activities increased by 39.53% to ¥247,958,852.87 from ¥177,715,583.96 in the same period last year[10] - Cash inflow from operating activities totaled 1,003,722,549.28, down from 1,270,327,838.43 in the previous period, representing a decrease of approximately 21%[91] - The company reported a decrease in cash flow from operating activities due to a reduction in cash received from sales, which was 975,638,412.97 compared to 1,226,437,711.99 in the previous period[91] - Cash flow from investing activities showed a net outflow of -33,000,201.32, improving from -146,709,461.04 in the previous period[94] - Cash flow from financing activities resulted in a net inflow of 18,443,850.63, a significant decrease from 356,593,580.00 in the previous period[97] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,382,028,706.19, an increase of 1.37% from ¥5,309,290,285.34 at the end of the previous year[10] - The total liabilities decreased to CNY 1,781,254,807.75 from CNY 1,879,642,335.60, reflecting a reduction of about 5.2%[66] - The total equity attributable to shareholders increased to CNY 3,386,068,343.78 from CNY 3,224,119,367.21, representing an increase of approximately 5%[66] - The company's short-term borrowings rose to CNY 310,000,000.00 from CNY 300,000,000.00, reflecting an increase in debt[60] - The company's inventory decreased to CNY 578,961,524.83 from CNY 664,545,055.70, indicating a reduction in stock levels[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,531[14] - The company repurchased 1,575,157 shares at an average price below CNY 22 per share, totaling CNY 22.76 million, which is 0.27% of the total share capital[27] Regulatory Compliance and Commitments - The company has disclosed compliance with relevant laws and regulations regarding significant matters during the reporting period[23] - The company committed to repurchase all newly issued shares within five trading days if the prospectus contains false statements or omissions, with the repurchase price not lower than the public offering price plus interest[30] - The company will actively take legal measures to fulfill its commitments regarding the issuance and listing of shares, accepting supervision from regulatory authorities and investors[36] - The company has confirmed that all commitments have been fulfilled on time[36] Financial Management - The initial investment cost for securities investment in Guiyang Bank was CNY 93,600, with a current fair value of CNY 999,648, resulting in a report period profit of CNY 253,094[37] - The company has a total of CNY 20,500 in entrusted financial management, all sourced from idle self-owned funds[41] - The annualized return rate for the entrusted financial management product is 4.00%[41] Other Financial Metrics - The company reported a tax expense of 43,056,152.61, which is slightly higher than 41,210,039.74 from the previous year, representing an increase of about 4.48%[80] - The company recorded a financial expense of -1,286,871.13, compared to -5,535,347.32 in the previous year, indicating an improvement in financial costs[80]

Financial Performance - The company's operating revenue for 2019 was CNY 4,371,413,641.89, a decrease of 2.24% compared to 2018[29]. - The net profit attributable to shareholders for 2019 was CNY 565,422,018.73, representing a slight increase of 0.38% from the previous year[29]. - The net cash flow from operating activities increased by 13.29% to CNY 981,327,677.71 in 2019[29]. - The basic earnings per share for 2019 was CNY 0.97, up by 1.04% compared to 2018[29]. - Total assets at the end of 2019 reached CNY 5,309,290,285.34, an increase of 4.94% from the end of 2018[29]. - The net assets attributable to shareholders decreased by 1.49% to CNY 3,224,119,367.21 at the end of 2019[29]. - The company reported a quarterly revenue of CNY 1,220,297,863.15 in Q4 2019, showing a strong performance in the last quarter[34]. - Non-operating income for 2019 included government subsidies amounting to CNY 67,774,835.29[35]. - The gross profit margin for the pharmaceutical industry was 58.66%, with a year-on-year decrease of 0.53%[65]. - The total operating costs amounted to CNY 1,806,201,921.57, a decrease of 0.97% from CNY 1,823,795,317.08 in 2018[71]. Market Strategy and Expansion - The company plans to expand its market presence and enhance its product offerings in the coming years[9]. - The company is focused on research and development of new products and technologies to drive future growth[9]. - The company is expanding its product line and market presence through strategic marketing and academic promotion, enhancing its operational efficiency and market management[43]. - The company is actively developing new retail business models through e-commerce and O2O strategies to enhance direct sales to users[54]. - The company is focusing on the strategic expansion of its product lines in women's health and chronic disease medications, leveraging the strong user traffic from its children's medicine brand[121]. - The company plans to innovate its marketing model by enhancing user engagement and optimizing product offerings based on user needs, aiming for sustainable and stable growth[121]. Research and Development - The company has ongoing research projects for various new products, including Ibuprofen suspension and liver protection tablets, with clinical trials in progress[78][79]. - The company has developed over 50 health products in 2019, obtaining health food approvals for two products[80]. - R&D investment amounted to ¥118,251,842.36, a decrease of 3.00% compared to ¥121,913,564.33 in the previous year[82]. - R&D personnel accounted for 11.33% of total employees, a slight increase from 11.06% year-over-year[82]. - The R&D strategy has been upgraded to focus on consumer-centric approaches, emphasizing the development of high-quality medications in children's, women's, and chronic disease categories[122]. Risk Management - The company emphasizes the importance of risk awareness regarding industry policy changes and fluctuations in traditional Chinese medicine prices[9]. - The company has faced risks related to market fluctuations and regulatory changes, which may impact its future performance[9]. - The fluctuation in traditional Chinese medicine material prices poses a risk, and the company is implementing strategic reserves and planning for self-owned material bases to stabilize costs[123]. - The company is closely monitoring industry policy changes to mitigate risks associated with regulatory impacts on its operations and market dynamics[122]. Shareholder and Dividend Information - The company reported a cash dividend of 10 RMB per 10 shares (including tax) for all shareholders, with no bonus shares issued[9]. - The company's dividend payout ratio is set at 30% for 2019, reflecting a commitment to returning value to shareholders[139]. - The cash dividend payout ratio for 2019 was 107.03%, indicating that the cash dividends exceeded the net profit attributable to ordinary shareholders[156]. - The company plans to maintain the same cash dividend distribution of 10 CNY per 10 shares for the 2019 fiscal year, with the remaining distributable profits carried over to 2020[151]. - The company distributed a cash dividend of 10 CNY per 10 shares for the 2018 fiscal year, totaling 58.4 million CNY (including tax) based on a total share capital of 584 million shares[149]. Corporate Governance and Compliance - The company appointed Lixin Certified Public Accountants as the auditor for the 2019 fiscal year, with an audit fee of 1.43 million yuan[176]. - The company did not experience any significant accounting errors requiring retrospective restatement during the reporting period[174]. - The company has committed to fulfilling its promises regarding share repurchases and profit distributions as per regulatory requirements[162]. - The company will ensure compliance with all legal obligations and responsibilities related to its share issuance and listing[164]. - There were no significant changes in the company's internal control audit or financial advisory services during the reporting period[179]. Investment and Fund Management - The total amount of raised funds was RMB 1,333,345,000, with a net amount of RMB 1,248,632,750 after deducting underwriting and other issuance costs[97]. - The company has utilized RMB 2,657.23 million of the raised funds in the current period, with a remaining balance of RMB 12,509.40 million[100]. - The company has a remaining unused raised fund balance of RMB 8,867.46 million, which is stored in a dedicated account[97]. - The company has established a three-party supervision agreement for the management of raised funds with banks to ensure proper usage and oversight[100]. - The company reported that some investment projects did not meet expected benefits due to market competition and underutilization of existing capacity[104].

Financial Performance - Net profit attributable to shareholders was CNY 67,821,991.69, an increase of 8.24% year-on-year[10]. - Operating income for the reporting period was CNY 764,115,869.96, down 4.33% compared to the same period last year[10]. - Basic earnings per share were CNY 0.1161, reflecting an increase of 8.20%[10]. - The weighted average return on net assets was 2.24%, an increase of 0.17% compared to the previous year[10]. - Operating profit increased to ¥105,606,617.37, up 66.4% from ¥63,557,578.98 in the previous period[72]. - Net profit for the current period is ¥88,654,886.85, an increase of 38.8% compared to ¥63,945,586.70 in the previous period[72]. - The company reported a total comprehensive income of ¥88,814,228.90, compared to ¥64,195,838.14 in the previous period[76]. - Net profit for the period was ¥419,641,231.88, an increase of 14.6% compared to ¥366,216,000.28 in the same period last year[90]. - Basic earnings per share rose to ¥0.6393 from ¥0.5915, representing an increase of approximately 8.5%[112]. - The company reported a total comprehensive income of ¥419,984,650.45, compared to ¥366,548,937.41 in the previous year, marking a growth of about 14.6%[107]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,844,548,479.18, a decrease of 4.24% compared to the end of the previous year[10]. - The total liabilities decreased from CNY 1,622,238,596.78 to CNY 1,593,008,091.54, a reduction of approximately 1.6%[55]. - The total owner's equity decreased from CNY 3,436,893,476.33 to CNY 3,251,540,387.64, a decline of about 5.4%[58]. - The company's current assets totaled CNY 2.72 billion, down from CNY 3.05 billion at the end of December 2018, indicating a decline of about 10.77%[49]. - The total current liabilities decreased from CNY 1,214,107,256.79 to CNY 1,149,920,581.67, a reduction of about 5.3%[55]. - The total non-current liabilities increased from CNY 408,131,339.99 to CNY 443,087,509.87, an increase of approximately 8.6%[55]. - The company's retained earnings decreased from CNY 1,545,845,731.24 to CNY 1,335,168,824.34, a decrease of about 13.6%[58]. Cash Flow - The net cash flow from operating activities increased by 181.78% to CNY 24,301,216.79[10]. - Net cash flow from operating activities rose by 56.83% to ¥447,041,057.41 due to reduced cash payments for goods and services[25]. - Cash flow from operating activities generated ¥3,163,493,201.22, down from ¥3,482,767,282.17[128]. - Cash flow from investing activities resulted in a net outflow of -¥321,702,608.71, compared to -¥317,673,353.77 in the previous period[133]. - The ending cash and cash equivalents balance was ¥974,093,477.96, up from ¥652,497,777.48 in the previous year[133]. - The net cash flow from investment activities was 401,146,917.07, up from 275,402,243.90, showing a significant increase of 45.5%[139]. - The company paid 592,674,380.11 in dividends and interest, up from 292,866,709.58, showing a significant increase in cash distribution[142]. Shareholder Information - The total number of shareholders at the end of the reporting period was 38,745[15]. - The largest shareholder, Kuaihua Group Co., Ltd., held 45.41% of the shares[15]. - The company did not conduct any repurchase transactions among the top ten shareholders during the reporting period[22]. - The company committed to not transferring or managing its shares for 36 months post-listing, with a potential extension of the lock-up period if stock prices fall below the issue price[35]. - The company will fulfill its repurchase obligations within 60 days after the shareholders' meeting approves the relevant resolutions[34]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 59,942,652.20 during the reporting period[10]. - Other income increased by 541.31% to ¥47,925,530.63 mainly due to new government subsidies and deferred income amortization[25]. - The company reported other income of ¥47,925,530.63, significantly higher than ¥7,473,053.70 in the previous period, indicating a substantial increase[87]. Research and Development - Research and development expenses for the current period are ¥29,019,741.27, a slight decrease of 5.9% from ¥30,830,794.32 in the previous period[69]. - Research and development expenses for the period were ¥93,526,855.20, up from ¥90,920,054.89, indicating an increase of approximately 3.4%[87].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2019, representing a year-on-year increase of 15%[19]. - Net profit attributable to shareholders reached RMB 200 million, up 10% compared to the same period last year[19]. - The company's operating revenue for the reporting period was ¥2,386,999,908.78, representing a 2.18% increase compared to the same period last year[28]. - The net profit attributable to shareholders was ¥305,501,101.41, reflecting an 8.03% increase year-over-year[28]. - The net cash flow from operating activities increased significantly by 52.93%, reaching ¥422,739,840.62[28]. - The company achieved a revenue of ¥2,386,999,908.78, representing a year-on-year growth of 2.18%[56]. - The net profit attributable to shareholders reached ¥30,550.11 million, an increase of 8.03% compared to the previous year[56]. - The net cash flow from operating activities was ¥42,273.98 million, showing a significant growth of 52.93% year-on-year[56]. Market Expansion and Product Development - The company plans to expand its market presence by increasing the number of retail outlets by 20% by the end of 2019[19]. - The company has launched three new products in the first half of 2019, contributing to a 5% increase in market share[19]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[19]. - The company focused on children's medicine, with significant growth in the "Xiao Kuihua" children's medicine line, achieving market leadership in the "children's heat" medication segment[46]. - The company is actively expanding its market presence through strategic focus on core product categories and enhanced marketing management[40]. - The company plans to expand its product offerings in the maternal and infant health sector, aiming for a breakthrough in future growth[54]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation and new product development[19]. - Research and development investment increased by 7.35% to ¥64,507.11 million, reflecting the company's commitment to innovation[59]. Financial Management and Investments - The total assets at the end of the reporting period were ¥5,050,296,307.48, a slight decrease of 0.17% from the previous year[28]. - The net assets attributable to shareholders decreased by 8.50%, amounting to ¥2,994,787,634.51[28]. - Short-term borrowings rose by 166.67% to ¥400 million, primarily due to increased bank loans[59]. - The company has made significant investments in new plant constructions and equipment to support future growth initiatives[41]. - The company has not engaged in any securities or derivative investments during the reporting period[77][78]. - The total amount of raised funds is RMB 1,248.63 million, with a total investment of RMB 1,301.69 million during the reporting period[79]. - The company has generated financial income and interest revenue of RMB 34.79 million from the raised funds[79]. Environmental Responsibility - The company has implemented pollution prevention measures, with specific emissions monitored for nitrogen oxides and chemical oxygen demand[141]. - The total emissions of nitrogen oxides from Jiamusi subsidiary is 0.3799856 tons, well below the regulatory limit[141]. - The chemical oxygen demand emissions from Jiamusi subsidiary is 3.17521 tons, with a regulatory limit of 10.02 tons[141]. - The company has established a comprehensive environmental protection management system, ensuring compliance with national and local environmental regulations[151]. - The company is committed to environmental sustainability and has implemented emergency response plans for potential environmental incidents[155]. Shareholder and Governance Matters - The company reported a decrease in restricted shares from 67,221,254 (11.51%) to 50,612,355 (8.67%), a reduction of 16,608,899 shares[172]. - The total number of shares increased from 584,000,000 to 584,000,000, with no new shares issued[172]. - The largest shareholder,葵花集团有限公司, holds 45.41% of the shares, amounting to 265,200,000 ordinary shares[177]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[187]. - The company has maintained a stable management structure with no new appointments or resignations reported apart from Wan Yunguo[199]. - The overall shareholding structure remains unchanged, indicating a stable governance environment[194]. Community Engagement - In the first half of 2019, the company contributed over 80,000 yuan to poverty alleviation efforts, including cash donations and medical supplies[156]. - The company successfully helped five registered impoverished individuals in a local village to escape poverty during the reporting period[156].

股票代码：002737 股票简称：葵花药业 公告编号：2019-043 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，葵花药业集团股份有限公司（以下简称 "公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举办 的"2019 年黑龙江省上市公司投资者网上集体接待日"活动，现将有关事项公 告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司 本次投资者集体接待日活动，时间为 2019 年 6 月 19 日（周三）14:00 至 16:30。 届时公司副总经理、财务负责人张延辉先生，董事会秘书田艳女士将通过网 络在线问答互动的形式，与投资者就公司治理、发展经营情况、融资情况和可持 续发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实时回答投 资者的提问。 欢迎广大投资者积极参与。 特此公告。 葵花药业集团股份有限公司 董事会 2019 年 6 月 12 日 葵 ...